Icaritin, a Flavonoid Derived from the Herb Epimedium, Promotes Osteogenic Differentiation of MC3T3-E1 Cells
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Osteoporosis is a metabolic bone disease that is characterized by low bone mass resulting from an increase in bone resorption relative to bone formation. The most current therapies for osteoporosis have focused on inhibiting bone resorption by osteoclasts. The purpose of this study is to develop new anabolic agents for treatment of osteoporosis that have fewer risks compared to conventional therapies. We searched the natural products that were derived from the traditional Asian medicines which have been used for treatment of bone related diseases. Icaritin is a flavonoid glycoside derived from the herb Epimedium which has beneficial effects on bone formation. To determine the effect of icaritin on bone formation, we examined the effect of icaritin on MC3T3-E1 cell proliferation and differentiation. For determining the effects of icaritin on proliferation, we performed the MTT assay using MC3T3-E1 cells. To evaluate whether icaritin could promote the osteogenic differentiation of MC3T3-E1 cells, alkaline phosphatase (ALP) activity and mRNA expressions of Runx2, osteocalcin (OCN), RANKL, and osteoprotegerin (OPG) were determined. Icaritin increased MC3T3-E1 cell proliferation. Icaritin increased the ALP activity of MC3T3-E1 cells on 72 hour culture in osteogenic media. mRNA expression of Runx2 was increased after 24 hour culture with icaritin. mRNA expression of osteocalcin was increased after 72 hour culture with icaritin. In addition, icaritin increased the mRNA expressions of OPG and RANKL. However, icaritin increased the mRNA expression of OPG much more than that of RANKL, and then, it increased the OPG/RANKL ratio. These results suggest that icaritin promotes osteogenic differentiation of osteoblasts and decreases osteoclast formation regulated by osteoblasts.
Abstract
Osteoporosis is a metabolic bone disease that is characterized by low bone mass resulting from an increase in bone resorption relative to bone formation. The most current therapies for osteoporosis have focused on inhibiting bone resorption by osteoclasts. The purpose of this study is to develop new anabolic agents for treatment of osteoporosis that have fewer risks compared to conventional therapies. We searched the natural products that were derived from the traditional Asian medicines which have been used for treatment of bone related diseases. Icaritin is a flavonoid glycoside derived from the herb Epimedium which has beneficial effects on bone formation. To determine the effect of icaritin on bone formation, we examined the effect of icaritin on MC3T3-E1 cell proliferation and differentiation. For determining the effects of icaritin on proliferation, we performed the MTT assay using MC3T3-E1 cells. To evaluate whether icaritin could promote the osteogenic differentiation of MC3T3-E1 cells, alkaline phosphatase (ALP) activity and mRNA expressions of Runx2, osteocalcin (OCN), RANKL, and osteoprotegerin (OPG) were determined. Icaritin increased MC3T3-E1 cell proliferation. Icaritin increased the ALP activity of MC3T3-E1 cells on 72 hour culture in osteogenic media. mRNA expression of Runx2 was increased after 24 hour culture with icaritin. mRNA expression of osteocalcin was increased after 72 hour culture with icaritin. In addition, icaritin increased the mRNA expressions of OPG and RANKL. However, icaritin increased the mRNA expression of OPG much more than that of RANKL, and then, it increased the OPG/RANKL ratio. These results suggest that icaritin promotes osteogenic differentiation of osteoblasts and decreases osteoclast formation regulated by osteoblasts.
참고문헌 (20)
- Milat F, "Osteoporosis treatment: a missed opportunity", Med J Aust, 205, pp.185~190 (2016)
- Michael McClung, "Bisphosphonate Therapy for Osteoporosis: Benefits, Risks, and Drug Holiday", The American Journal of Medicine, 126(1), pp.13~20 (2013), Elsevier BV[DOI]
- Huiping Ma, "The genus Epimedium: An ethnopharmacological and phytochemical review", Journal of Ethnopharmacology, 134(3), pp.519~541 (2011), Elsevier BV[DOI]
- Jia M, "Potential Antiosteoporotic Agents from Plants: A Comprehensive Review", Evid Based Complement Alternat Med, 2012, pp.1~28 (2012)[DOI]
- Chenrui Li, "Pharmacological effects and pharmacokinetic properties of icariin, the major bioactive component in Herba Epimedii", Life Sciences, 126, pp.57~68 (2015), Elsevier BV[DOI]
- Zhang G, "Constitutional flavonoids derived from Epimedium dose-dependently reduce incidence of steroid-associated osteonecrosis not via direct action by themselves on potential cellular targets", PLoS One, 4(7), pp.1~11 (2009)[DOI]
- K POOLE, "Parathyroid hormone — a bone anabolic and catabolic agent", Current Opinion in Pharmacology, 5(6), pp.612~617 (2005), Elsevier BV[DOI]
- T. Ponnapakkam, "Treating osteoporosis by targeting parathyroid hormone to bone", Drug Discovery Today, 19(3), pp.204~208 (2014), Elsevier BV[DOI]
- Anderson GL, "Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial", JAMA, 291, pp.1701~1712 (2004)
- Beral V, "Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study", Lancet, 362, pp.419~427 (2003)
- Tsai-Pei Hsieh, "Icariin isolated from Epimedium pubescens regulates osteoblasts anabolism through BMP-2, SMAD4, and Cbfa1 expression", Phytomedicine, 17(6), pp.414~423 (2010), Elsevier BV[DOI]
- Sao-Keng Mok, "Icariin protects against bone loss induced by oestrogen deficiency and activates oestrogen receptor-dependent osteoblastic functions in UMR 106 cells", British Journal of Pharmacology, 159(4), pp.939~949 (2010), Wiley[DOI]
- Leilei Xia, "Icariin delivery porous PHBV scaffolds for promoting osteoblast expansion in vitro", Materials Science and Engineering: C, 33(6), pp.3545~3552 (2013), Elsevier BV[DOI]
- Jing An, "Natural products for treatment of osteoporosis: The effects and mechanisms on promoting osteoblast-mediated bone formation", Life Sciences, 147, pp.46~58 (2016), Elsevier BV[DOI]
- Hui-Hui Xiao, "Flavonoids from Herba epimedii selectively activate estrogen receptor alpha (ERα) and stimulate ER-dependent osteoblastic functions in UMR-106 cells", The Journal of Steroid Biochemistry and Molecular Biology, 143, pp.141~151 (2014), Elsevier BV[DOI]
- Zhidi Wu, "Icaritin induces MC3T3-E1 subclone14 cell differentiation through estrogen receptor-mediated ERK1", 2 and p38 signaling activation, 2017, pp.94, 1~9[DOI]
- Dong Zheng, "The beneficial effect of Icariin on bone is diminished in osteoprotegerin-deficient mice", Bone, 51(1), pp.85~92 (2012), Elsevier BV[DOI]
- Tsai-Pei Hsieh, "Icariin inhibits osteoclast differentiation and bone resorption by suppression of MAPKs", NF-κB regulated HIF-1α and PGE2 synthesis, 2011, pp.18(2-3), 176~185[DOI]
- Yasuda H, "Osteoclast differentiation factor is a ligand for osteoprotegerin", osteoclastogenesis-inhibitory factor and is identical to TRANCE, Proc Natl Acad Sci U S A, pp.1998, 95(7)[DOI]
- Aubin JE, "Osteoprotegerin and its ligand : A new paradigm for regulation of osteoclastogenesis and bone resorption", Osteoporos Int, 11(11), pp.905~913 (2000)